Axsome Therapeutics' SWOT analysis: stock poised for growth amid CNS breakthroughs
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company has been gaining significant ...
Axsome Therapeutics stock hits 52-week high at $105.18
Axsome Therapeutics Inc . (NASDAQ:AXSM) stock soared to a 52-week high, reaching a price level of $105.18. The biopharmaceutical company, with a market capitalization of $5 billion, has demonstrated ...
Strong Prescription Growth and Market Acceptance Drive Buy Rating for Axsome Therapeutics
Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on AXSM stock, giving a Buy rating on January 24.Invest with ...
Promising Outlook for Axsome Therapeutics Driven by Auvelity’s Strong Market Performance and Growth Prospects
Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) yesterday and set a price target ...
Axsome Shares Rise 19% in a Month: What's Driving the Rally?
AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while ...